Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822335 | 1.00 | RET (0.41) | RETPI4KAXDHLRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL30822451 | 0.98 | RET (0.39) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL12726134 | 0.79 | PDK2 (0.41) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL12765587 | 0.79 | RET (0.38) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL28682281 | 0.77 | KDM4E (0.36) | PI4KBALDH1A1KDM4EADORA2AADORA1 | |
| SCHEMBL13210047 | 0.75 | HASPIN (0.37) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL7255671 | 0.72 | HPGDS (0.49) | KDRAURKBALDH1A1ADORA2AADORA1 | |
| SCHEMBL26675437 | 0.71 | PTPN11 (0.43) | PDPK1CDK2ALDH1A1KDM4EGAA | |
| SCHEMBL29768195 | 0.71 | PTPN11 (0.43) | PDPK1CDK2ALDH1A1KDM4EGAA | |
| SCHEMBL31001140 | 0.71 | RET (0.52) | RETPI4KAXDHLRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926734-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | Amgen Inc. (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-13 | — | — | US | disclosed |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-12-10 | — | — | US | disclosed |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-29 | — | — | US | disclosed |
| WO-2023039548-A1 | KINASE INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | FRED HUTCHINSON CANCER CENTER (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022036310-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036313-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036312-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3328496-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-3030241-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021149-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| EP-1926734-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | Amgen Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | RET 1019/4885PI4KA 753/4885XDH 2465/4885 |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | BTK, XIAP, SYK | RET 1154/4885PI4KA 852/4885XDH 2613/4885 |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | RET 1019/4885PI4KA 753/4885XDH 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.